TuHURA Biosciences (NASDAQ:HURA) Trading 0.5% Higher – Here’s Why

TuHURA Biosciences, Inc. (NASDAQ:HURA) shares shot up 0.5% during mid-day trading on Thursday . The stock traded as high as $0.7763 and last traded at $0.7604. 333,894 shares changed hands during mid-day trading, a decline of 1% from the average session volume of 338,296 shares. The stock had previously closed at $0.7568.

Analyst Ratings Changes

A number of research firms have commented on HURA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Wednesday, October 8th. Wall Street Zen cut TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, December 14th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective (down previously from $12.00) on shares of TuHURA Biosciences in a report on Friday, January 9th. Finally, Maxim Group dropped their target price on shares of TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, TuHURA Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

TuHURA Biosciences Trading Up 0.0%

The company’s 50-day moving average is $1.31 and its two-hundred day moving average is $2.14. The stock has a market capitalization of $38.98 million, a P/E ratio of -1.52 and a beta of 0.03.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of HURA. Geode Capital Management LLC raised its stake in shares of TuHURA Biosciences by 111.4% during the second quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock valued at $1,300,000 after purchasing an additional 307,260 shares in the last quarter. New York State Common Retirement Fund acquired a new position in TuHURA Biosciences during the 2nd quarter valued at about $97,000. Marshall Wace LLP bought a new stake in shares of TuHURA Biosciences during the 2nd quarter worth about $79,000. Vanguard Group Inc. raised its holdings in TuHURA Biosciences by 1.6% during the third quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock worth $5,629,000 after purchasing an additional 35,426 shares in the last quarter. Finally, Brighton Jones LLC bought a new stake in TuHURA Biosciences during the third quarter worth approximately $69,000. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.